Dyne Therapeutics, Inc. (DYN)

SEC fundamentals · as filed in 10-Q FY2026, period ended Jun 30, 2026 · updated Oct 7, 2026

Verified against EDGAR
Total Assets
$994.0M
Stockholders' Equity
$702.2M
Cash & Equivalents
$676.1M
Long-Term Debt
$199.3M

as filed in 10-Q FY2026, period ended Jun 30, 2026 · View filings on EDGAR ↗

In its 10-Q for the period ended Jun 30, 2026, Dyne Therapeutics, Inc. reported net income of -$178.6M and total assets of $994.0M. Every figure below is taken directly from Dyne Therapeutics, Inc.'s SEC filings: each links to the source document on EDGAR.

Revenue and net income by fiscal year

As reported in each year’s annual filing · USD

Fiscal yearRevenueNet income
FY2025—-$446.2M
FY2024—-$317.4M
FY2023—-$235.9M
FY2022—-$168.1M
FY2021—-$149.3M
FY2020—-$59.4M
FY2019—-$14.9M

Recent SEC filings

Filed by the registrant · newest first · insider forms and holder schedules not included

FormFiledSource
8-KSep 29, 2026on EDGAR ↗
8-KJul 29, 2026on EDGAR ↗
10-QJul 29, 2026on EDGAR ↗
8-KJul 22, 2026on EDGAR ↗
8-KJul 20, 2026on EDGAR ↗
8-KJun 22, 2026on EDGAR ↗
8-KJun 17, 2026on EDGAR ↗
8-KJun 8, 2026on EDGAR ↗
8-KJun 3, 2026on EDGAR ↗
10-QMay 11, 2026on EDGAR ↗

All filings on EDGAR ↗

Balance Sheet

as of Jun 30, 2026 · 10-Q

Total Assets$994.0Msource ↗
Stockholders’ Equity$702.2Msource ↗
Cash & Equivalents$676.1Msource ↗
Long-Term Debt$199.3Msource ↗

Income Statement

10-Q (quarterly) · period ended Jun 30, 2026

Revenue—source ↗
Net Income-$178.6Msource ↗
Operating Income-$181.7Msource ↗
Gross Profit—source ↗
Cost of Revenue—source ↗
R&D Expense$152.2Msource ↗

Per Share & Cash Flow

10-Q (quarterly) · period ended Jun 30, 2026

EPS (diluted)$-1.08source ↗
EPS (basic)$-1.08source ↗
Shares Outstanding186.7Msource ↗
Cash from Operations-$130.3Msource ↗
Cash from Financing$58.1Msource ↗
Cash from Investing-$4.8Msource ↗

Insider activity

Form 4 open-market activity, last 180 days

Buys
5
Sells
67
Net shares
-4.9M

Restatement history

Point-in-time

No material restatements detected across 144 annual fact-keys: this company's as-filed numbers have held between filings. Point-in-time and as-of history are available via the API.

Deeper fundamentals

A free API key reaches DYN’s revenue, margin and free-cash-flow trajectory (newest 3 fiscal years) and its leverage, liquidity and return ratios (newest 4 quarters). Analyst extends those to up to 20 years and 20 quarters, and adds the Piotroski F-score and accruals quality score. As-of fundamentals at any past date are on Free too, up to 10 lookups a day; Analyst removes that cap and adds the original-vs-restated detail, across the whole SEC universe.

Get a free API key →See plans

Programmatic access

Everything on this page is served by the Distill API and by the MCP server at mcp.distillmarkets.com. A free key is issued at sign-up with no card; the full reference is in the docs.

These fundamentals, as filed
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
  https://api.distillmarkets.com/api/v1/sec/fundamentals/DYN

MCP tool: get_sec_fundamentals ticker=DYN

The same figures as they were known on any past date
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
  https://api.distillmarkets.com/api/v1/sec/fundamentals/DYN/as-of/YYYY-MM-DD

MCP tool: get_asof_fundamentals ticker=DYN as_of=YYYY-MM-DD

Fiscal-year trajectory: revenue, margins, free cash flow
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
  https://api.distillmarkets.com/api/v1/sec/fundamentals/DYN/history

MCP tool: get_fundamentals_history ticker=DYN

Leverage, liquidity, margin and return ratios
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
  https://api.distillmarkets.com/api/v1/sec/financial-health/DYN

MCP tool: get_financial_health ticker=DYN

Not investment advice. Figures are shown as filed with the SEC; see the EDGAR source links for the original documents. Data may lag the latest filing.